ILC Dover, an Ingersoll Rand business involved in design and production for biopharmaceutical, pharmaceutical, and medical device markets, announced on Tuesday that it recently invested in two new core capabilities: Water for Injection (WFI) quality water, and custom chemical solutions.

According to ILC Dover, WFI quality water is a critical component in pharmaceutical manufacturing, enabling the production of injectable therapies and other high-purity applications that demand the highest quality standards. In addition, high-purity, cGMP-aligned contract formulation and filling services are critical to regulated medical devices, diagnostics, and biopharmaceutical applications.

ILC Dover's new services position the company to provide integrated, end-to-end support to pharmaceutical and biologics, medical device, and diagnostics companies as they scale production and advance next-generation products.

"Life sciences innovation depends on absolute quality, reliability, and compliance," said Ciro Ahumada, vice president and general manager, Biopharma & Pharma Solutions, Ingersoll Rand. "By adding WFI and custom chemical solutions manufacturing to our portfolio, we are extending our ability to support customers across the full lifecycle of drug development and commercial production."